Ads
related to: celgene salethomasnet.com has been visited by 10K+ users in the past month
Search results
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022
Investor's Business Daily· 2 years agoBristol Myers Squibb reaffirmed expectations for a $10 billion pitfall from its generics-facing...
Should Investors Buy Bristol Myers Squibb Stock?
Zacks via Yahoo Finance· 2 years agoBMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
Investor's Business Daily· 1 year agoIt's a new day at Bristol Myers Squibb, according to a company executive. But BMY stock remains...
How These Acquisitions Are Changing the Outlook for Bristol Myers Squibb
Motley Fool· 2 years agoPharmaceutical giant Bristol Myers Squibb's (NYSE: BMY) purchase of Celgene turned it into a dominant player in oncology and hematology, and this year, the company has aggressively strengthened ...
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
Zacks via Yahoo Finance· 2 years agoBiotech bigwig Bristol Myers BMY has had a decent run this year despite one of its top drugs...
11 Most Promising Cancer Stocks According to Analysts
Insider Monkey via Yahoo Finance· 1 year agoIn this article, we discuss 11 most promising cancer stocks according to analysts. If you want to...
Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?
Zacks via Yahoo Finance· 1 year agoBristol-Myers Squibb BMY has recently been enjoying a string of positive regulatory updates. The...
IBD Stock Of The Day: Bristol Myers Eyes Breakout After $4.1 Billion Buyout
Investor's Business Daily· 2 years agoBristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting...
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
InvestorPlace via Yahoo Finance· 11 months agoPharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to...
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Reuters via Yahoo Finance· 9 months agoBristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal...
